Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

In a 1 a.m. Eastern time press release, Regeneron said one Phase 3 trial of itepekimab, in adult former smokers with COPD, met the primary target by showing significant reduction of 27% in the ...